The use of combination therapy in the treatment of postmenopausal osteoporosis

Endocrine

Volumn 41, Issue 1, 2012, Pages 11-18

  Compston, Juliet ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anabolics; Anti resorptives; Bone mineral density; Combination therapy; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ANTIRESORPTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; HORMONE; METHYLTESTOSTERONE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMUR NECK; GOUT; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LUMBAR SPINE; MONOTHERAPY; OSSIFICATION; OSTEOLYSIS; POROSITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84862651682     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9554-2     Document Type: Review

References (44)

1. J.E. Compston, N.B. Watts, Combination therapy for postmenopausal osteoporosis. Clin. Endo. 56, 565-569 (2002) (Pubitemid 34595720)
2. S.J. Wimalawansa, Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am. J. Med. 99, 36-42 (1995)
3. S.J. Wimalawansa, A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am. J. Med. 104, 219-226 (1998) (Pubitemid 28163165)
4. R. Lindsay, F. Cosman, R.A. Lobo, B.W. Walsh, S.T. Harris, J.E. Reagan, C.L. Liss, M.E. Melton, C.A. Byrnes, Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J. Clin. Endocrinol. Metab. 84, 3076-3081 (1999) (Pubitemid 30646926)
5. H.G. Bone, S.L. Greenspan, C. McKeever, N. Bell, M. Davidson, R.W. Downs, R. Emkey, P.J. Meunier, S.S. Miller, A.L. Mulloy, R.R. Recker, S.R. Weiss, N. Heyden, T. Musliner, S. Suryawanshi, A.J. Yates, A. Lombardi, Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group. J. Clin. Endocrinol. Metab. 85, 720-726 (2000) (Pubitemid 32273660)
6. S.L. Greenspan, N.M. Resnick, R.A. Parker, Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. J. Am. Med. Assoc. 289, 2525-2533 (2003) (Pubitemid 37430154)
7. S.T. Harris, E.F. Eriksen, M. Davidson, M.P. Ettinger, A.H. Moffett Jr, D.J. Baylink, C.E. Crusan, A.A. Chines, Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 86, 1890-1897 (2001) (Pubitemid 32472892)
8. O. Johnell, W.H. Scheele, Y. Lu, J.Y. Reginster, A.G. Need, E. Seeman, Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87, 985-992 (2002) (Pubitemid 36121052)
9. N.B. Watts, M. Notelovitz, M.C. Timmons, W.A. Addison, B. Wiita, L.J. Downey, Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet. Gynecol. 85, 529-537 (1995)
10. M.Meschia, M. Brincat, P. Barbacini, P.G. Crossignani,W. Albisetti, A clinical trial on the effects of a combination of elcatonin (carbocalcitonin)and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif. Tissue Int. 53, 17-20 (1993) (Pubitemid 23187326)
11. M. Tuppurainen, K. Härmä, M. Komulainen, V. Kiviniemi, H. Kröger, R. Honkanen, E. Alhava, J. Jurvelin, S. Saarikoski, Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. Maturitas 66, 423-430 (2010)
12. D.L. Kendler, C. Roux, C.L. Benhamou, J.P. Brown, M. Lillestol, S. Siddhanti, H.S. Man, J.S. Martin, H.G. Bone, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone. Miner. Res. 25, 72-81 (2010)
13. J.Y. Reginster, R. Deroisy, M. Dougados, I. Jupsin, J. Colette, C. Roux, Prevention of early postmenopausal bone loss by strontium ranelate: the randomised, two-year, double-masked, dose-ranging, placebo-controlled PREVOS study. Osteoporos. Int. 13, 925-931 (2002) (Pubitemid 36050269)
14. P.J. Meunier, D.O. Slosman, P.D. Delmas, J.L. Sebert, M.L. Brandi, C. Albanese, R. Lorenc, S. Pors-Neilsen, M.C. de Vernejoul, A. Roces, J.Y. Reginster, Strontium ranelate: dosedependent effects in established postmenopausal vertebral osteoporosis- a 2-year randomised placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060-2066 (2002) (Pubitemid 34521489)
15. G.M. Blake, J.E. Compston, I. Fogelman, Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J. Bone Miner. Res. 24, 1354-1357 (2009)
16. E.T. Middleton, S.A. Steel, M. Aye, S.M. Doherty, The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J. Bone Miner. Res. 25, 455-462 (2010)
17. E.T. Middleton, S.A. Steel, M. Aye, S.M. Doherty, The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos. Int. 19(12), 1811-1812 (2011)
18. B. Ettinger, J. San Martin, G. Crans, I. Pavo, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19, 745-751 (2004) (Pubitemid 41094385)
19. F. Cosman, J. Nieves, L. Woelfert, V. Shen, R. Lindsay, Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13, 1051-1055 (1998) (Pubitemid 28265285)
20. F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94, 3772-3780 (2009)
21. F. Cosman, J. Nieves, M. Zion, L. Woelfert, M. Luckey, R. Lindsay, Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353, 566-575 (2005) (Pubitemid 41138938)
22. P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93, 3785-3793 (2008)
23. B.M. Obermayer-Pietsch, F. Marin, E.V. McCloskey, P. Hadji, J. Farrerons, S. Boonen, M. Audran, C. Barker, A.D. Anastasilakis, W.D. Fraser, T. Nickelsen, EUROFORS Investigators, Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J. Bone Miner. Res. 23, 1591-1600 (2008)
24. S. Boonen, F. Marin, B. Obermayer-Pietsch, M.E. Simões, C. Barker, E.V. Glass, P. Hadji, G. Lyritis, H. Oertel, T. Nickelsen, E.V. McCloskey, EUROFORS Investigators, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93, 852-860 (2008) (Pubitemid 351398563)
25. R. Lindsay, J. Nieves, C. Formica, E. Henneman, L. Woelfert, V. Shen, D. Dempster, F. Cosman, Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350, 550-555 (1997) (Pubitemid 27348431)
26. F. Cosman, J. Nieves, L. Woelfert, C. Formica, S. Gordon, V. Shen, R. Lindsay, Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16, 925-931 (2001) (Pubitemid 32332303)
27. R. Prince, A. Sipos, A. Hossain, U. Syversen, S. Ish-Shalom, E. Marcinowska, J. Halse, R. Lindsay, G.P. Dalsky, B.H. Mitlak, Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J. Bone Miner. Res. 20, 1507-1513 (2005) (Pubitemid 41243539)
28. D.M. Black, J.P. Bilezikian, K.E. Ensrud, S.L. Greenspan, L. Palermo, T. Hue, T.F. Lang, J.A. McGowan, C.J. Rosen, One year of alendronate after one year of parathyroid hormone (1-84)for osteoporosis. N. Engl. J. Med. 353, 555-565 (2005) (Pubitemid 41138937)
29. B.Z. Leder, R.M. Neer, J.J. Wyland, H.W. Lee, S.M. Burnett-Bowie, J.S. Finkelstein, Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J. Clin. Endocrinol. Metab. 94, 2915-2921 (2009)
30. R. Lindsay, W.H. Scheele, R. Neer, G. Pohl, S. Adami, C. Mautalen, J.Y. Reginster, J.J. Stepan, S.L. Myers, B.H. Mitlak, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164, 2024-2030 (2004) (Pubitemid 39390560)
31. R.S. Rittmaster, M. Bolognese, M.P. Ettinger, D.A. Hanley, A.B. Hodsman, D.L. Kendler, C.J. Rosen, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 85, 2129-2134 (2000) (Pubitemid 32269232)
32. R. Eastell, T. Nickelsen, F. Marin, C. Barker, P. Hadji, J. Farrerons, M. Audran, S. Boonen, K. Brixen, J.M. Gomes, B. Obermayer-Pietsch, A. Avramidis, G. Sigurdsson, C.C. Glüer, Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J. Bone Miner. Res. 24, 726-736 (2009)
33. E.S. Kurland, S.L. Heller, B. Diamond, D.J. McMahon, F. Cosman, J.P. Bilezikian. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos. Int. 15, 992-997 (2004) (Pubitemid 40064654)
34. P.D. Delmas, P. Vergnaud, M.E. Arlot, P. Pastoureau, P.J. Meunier, M.H. Nilssen, The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16, 603-610 (1995)
35. C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20, 1905-1911 (2005) (Pubitemid 41532775)
36. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207-1215 (2003) (Pubitemid 37152030)
37. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, R.M. Neer, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349, 1216-1226 (2003) (Pubitemid 37152031)
38. J.S. Finkelstein, J.J. Wyland, H. Lee, R.M. Neer, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95, 1838-1845 (2010)
39. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guañabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503-511 (2011)
40. S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanley, R. Lindsay, J.R. Zanchetta, C.M. Blosch, A.L. Mathisen, S.A. Morris, T.B. Marriott, Treatment of Osteoporosis with Parathyroid Hormone Study Group, Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326-339 (2007) (Pubitemid 351650593)
41. D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, M.C. Nevitt, D.C. Bauer, H.K. Genant, W.L. Haskell, R. Marcus, S.M. Ott, J.C. Torner, S.A. Quandt, T.F. Reiss, K.E. Ensrud, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348, 1535-1541 (1996) (Pubitemid 26411651)
42. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, P.J. Meunier, J.Y. Reginster, Hip Intervention Program Study Group, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344, 333-340 (2001) (Pubitemid 32107641)
43. D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, F. Cosman, P. Lakatos, P.C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T.F. Hue, D. Sellmeyer, E.F. Eriksen, S.R. Cummings, HORIZON Pivotal Fracture Trial, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809-1822 (2007) (Pubitemid 46698462)
44. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001) (Pubitemid 32402100)